Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00261937

Enrollment

Unknown

Registered

2005-12-06

Start date

2005-12-31

Completion date

2006-04-30

Last updated

2013-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis

Brief summary

We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.

Interventions

DRUGInhaled Furosemide vs Placebo (Normal Saline)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

1 Days to 12 Months

Healthy volunteers

Inclusion criteria

* Age: 0-12 months. * Infants who are otherwise healthy * Infants with chronic lung disease of prematurity (BPD) will be included, but will be analyzed separately. * Parents signed a written informed consent.

Exclusion criteria

* • Other previous or co-morbidity, specifically: respiratory (other than BPD, like Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.

Design outcomes

Primary

Measure	Time frame
Clinical respiratory effects	—

Secondary

Measure	Time frame
1. The duration of hospitalization	—
2. Time weaned off oxygen	—
3. Time to full enteral feeding	—

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026